MatthewGenyehMeiMD

Oncology • Duarte, CA

Clinical Associate Professor

Join to view full profile

Dr. Mei is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mei's full profile

Already have an account?

Office
Division of Lymphoma
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-389-3059

Education & Training

Los Angeles County-Harbor-UCLA Medical Center 1Fellowship, Hematology and Medical Oncology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2007 - 2010
Case Western Reserve University School of MedicineClass of 2007

Certifications & Licensure

CA State Medical License 2009 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA Start of enrollment: 2018 Oct 30
Active, not recruiting
Phase 1
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Start of enrollment: 2022 Jul 25
Active, not recruiting
Phase 1
Roles: Contact
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed Start of enrollment: 2022 Jan 03
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2023 May 01
Withdrawn
Phase 1, Phase 2
Roles: Principal Investigator, Contact
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Recruiting
Phase 2
Roles: Contact
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Start of enrollment: 2023 Oct 10
Recruiting
Phase 2
Roles: Contact
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study Start of enrollment: 2023 May 18
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma Start of enrollment: 2024 Aug 24
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

14 citations
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.
Ibrahim Aldoss, Dongyun Yang, Vanina Tomasian, Sally Mokhtari, Ryan Jackson
Blood Advances. 2022-09-13
53 citations
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
Ibrahim Aldoss, Sanjeet Dadwal, Jianying Zhang, Bernard Tegtmeier, Matthew Mei
Blood Advances. 2019-12-10
44 citations
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
Haris Ali, Ibrahim Aldoss, Dongyun Yang, Sally Mokhtari, Samer K. Khaled
Blood Advances. 2019-01-08

Abstracts/Posters

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged _60 YearsClinically Relevant Abstract
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...
Matthew Mei, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

City of Hope Doctors Present New Research on Cancer ImmunotherapiesNovember 4th, 2021
City of Hope Doctors Present Research on New Immunotherapies at American Society of Hematology ConferenceDecember 9th, 2019
Rituximab Key to Survival After Transplant for Mantle Cell LymphomaNovember 16th, 2017
Join now to see all